MYRIAD GENETICS INC — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Vishal Sikri, who served as SVP of Product for one year, was promoted to Executive Vice President - Commercial effective September 16, 2026. Brian Donnelly, Chief Commercial Officer since May 2025, is departing September 21, 2026. The company reaffirmed full-year 2026 financial guidance.
Why this rating
Routine executive transition; internal promotion with no financial impact stated. No revenue/cost data; guidance reaffirmed. Ordinary organizational change.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.